Effect of Pemafibrate, a Selective Peroxisome Proliferator-activated Receptor ? Modulator (SPPARM?), on the Lipid Profile, Liver Function, and Liver Fibrosis among Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Translation [Internet]. 2025 Jun. 30 [cited 2026 Jul. 27];13(S3). Available from: https://dev.openjournals.utoledo.edu/index.php/translation/article/view/1397